KRAS mutations: an old oncogene becomes a new predictive biomarker.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Molecular Diagnostics

• Publication date

  2008-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2353/jmoldx.2008.080105PMID 18832458PMCID PMC2570631
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Genetic predictors of MEK dependence in non-small cell lung cancer.

  2008cited by this paper
• Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

  2008cited by this paper
• KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

  2008cited by this paper
• KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

  2008cited by this paper
• EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Rapid screening assay for KRAS mutations by the modified smart amplification process.

  2008cited by this paper
• Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

  2008cited by this paper
• KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

  2008cited by this paper
• Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

  2008cited by this paper
• Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

  2008cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

  2007cited by this paper
• Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

  2007cited by this paper
• Cetuximab for the treatment of colorectal cancer.

  2007cited by this paper
• KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

  2007cited by this paper
• Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method

  2007cited by this paper
• Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.

  2007cited by this paper
• Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

  2007cited by this paper
• Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

  2006cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation

  2006cited by this paper
• Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

  2006cited by this paper
• Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper

• Identification of Crucial Drug Targets and Pathways to Reprogram Drug Resistance Through Epigenetic Modulation in Advanced Lung Cancer Using Integrated Bioinformatics Approach

  2026cites this paper
• Reconfigurable Nucleic Acid Nanoparticles with Therapeutic RNAi Responses to Intracellular Disease Markers

  2025cites this paper
• Pharmacogenomics and Personalized Medicine

  2024cites this paper
• Oridonin enhances cytotoxic activity of natural killer cells against lung cancer.

  2023cites this paper
• Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice

  2023cites this paper
• Identification of Potent Inhibitors Targeting EGFR and HER3 for Effective Treatment of Chemoresistance in Non-Small Cell Lung Cancer

  2023cites this paper
• Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches

  2022cites this paper
• Toward Early Diagnosis of Colorectal Cancer: Focus on Optical Nano Biosensors.

  2022cites this paper
• Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing

  2022cites this paper
• A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC

  2021cites this paper
• Prognostic Value of Autophagy, Microsatellite Instability, and KRAS Mutations in Colorectal Cancer

  2021cites this paper
• Potential of PAR-4 as a Therapeutic Target for Pancreatic Cancer

  2021cites this paper
• Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan

  2020cites this paper
• Structure of two G-quadruplexes in equilibrium in the KRAS promoter

  2020cites this paper
• Tumor Protein p53 and K -ras Gene Mutations in Peruvian Patients with Gallbladder Cancer

  2019cites this paper
• Validity of an NGS-based multiple gene panel in identifying actionable mutations for patients with NSCLC in a Chinese hospital

  2019cites this paper
• Characteristics and Outcomes of Patients With Metastatic KRAS‐Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

  2019cites this paper
• KRAS mutation

  2019cites this paper
• Implementing Companion Diagnostic Testing in the Clinic

  2019cites this paper
• The Papanicolaou Society of Cytopathology System for Reporting Respiratory Cytology

  2019cites this paper
• Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma

  2018cites this paper
• Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene

  2018cites this paper
• Recommendations for Ancillary Testing

  2018cites this paper
• New Targets in Non-Small Cell Lung Cancer.

  2017cites this paper
• Non-small cell lung cancer: current treatment and future advances.

  2016cites this paper
• Longitudinal molecular characterization of endoscopic specimens from colorectal lesions.

  2016cites this paper
• An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine

  2016cites this paper
• NON-SMALL CELL LUNG CANCER: PRESENT TREATMENT AND UPCOMING IMPROVEMENTS

  2016cites this paper
• Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer

  2016cites this paper
• Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA

  2016cites this paper
• Diagnosis and Molecular Classification of Lung Cancer.

  2016cites this paper
• The clinical significance of K-ras mutation in endometrial "surface epithelial changes" and their associated endometrial adenocarcinoma.

  2016cites this paper
• Lung and Mediastinal Tumors

  2015cites this paper
• Pleural involvement in lung cancer.

  2015cites this paper
• Assessment of EGFR and KRAS mutation status from FNAs and core‐needle biopsies of non‐small cell lung cancer

  2015influential citation
• Ganetespib: research and clinical development

  2015cites this paper
• Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India.

  2014cites this paper
• Molecular alterations in non-small cell lung carcinomas of the young.

  2014cites this paper
• Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing.

  2014cites this paper
• Diagnostic accuracy of high resolution melting analysis for detection of KRAS mutations: a systematic review and meta-analysis

  2014cites this paper
• Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma

  2013cites this paper
• A 75-year-old man with progressive bronchioalveolar carcinoma.

  2013cites this paper
• KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma

  2013cites this paper
• KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.

  2013cites this paper
• KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem

  2012cites this paper
• Laboratory methods for KRAS mutation analysis

  2011cites this paper
• Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.

  2010cites this paper
• PAR-4 as a possible new target for pancreatic cancer therapy

  2010cites this paper
• Lung cancer in 'Never-smokers': molecular factors trump risk factors.

  2010cites this paper
• A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma.

  2010cites this paper
• Validation of blood testing for K-ras mutations in colorectal and pancreatic cancer.

  2010cites this paper
• 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency

  2010cites this paper
• FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.

  2009cites this paper
• Recherche des mutations de KRAS dans les cancers colorectaux

  2009cites this paper
• Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non–Small Cell Lung Cancer

  2009cites this paper
• KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803

  2009cites this paper